srg-30 Antibody

What is the SRG rat model and how does it differ from traditional mouse models for PDX studies?

The SRG rat is a Sprague-Dawley Rag2/Il2rg double knockout model that lacks mature B cells, T cells, and circulating NK cells, making it highly immunodeficient and suitable for xenotransplantation studies . Unlike traditional mouse models, the SRG rat can support significantly larger tumor volumes—nearly ten times the volume (or double the diameter) allowed in mice—and demonstrates higher engraftment rates and faster tumor growth kinetics . This makes it particularly valuable for establishing patient-derived xenograft (PDX) banks with less passage-related drift than mouse models. Additionally, the SRG rat's size allows for serial blood and tumor tissue sampling from the same animal, enabling temporal assessment of multiple parameters that would require separate animals in mouse models .

How does the SRG rat model affect engraftment rates and tumor growth compared to NSG mice?

Studies comparing the SRG rat and NSG mouse demonstrate that the SRG rat consistently supports higher engraftment rates and faster tumor establishment. In direct comparisons:

These enhanced engraftment properties are not due to greater immunodeficiency but appear related to improved tumor microenvironment interactions in the SRG rat .

How does the tumor microenvironment differ between PDX models grown in SRG rats versus NSG mice?

Histopathological and molecular characterization reveals significant differences in tumor microenvironment formation between the two host species. PDX tumors grown in SRG rats showed:

• Enhanced formation of vasculature and stromal components

• Morphological features more consistent with the originating patient tumors

• Less extensive central necrosis compared to the same tumors grown in NSG mice

• Different patterns of macrophage infiltration and distribution

• Distinct molecular signatures, including increased expression of TCIM and CXCL2, both associated with protumor formation and poor prognosis in patients

Single-cell spatial imaging further confirmed these differences, with tumors grown in SRG rats displaying gene expression profiles more closely resembling those of primary human tumors .

What molecular characterization methods should be employed to validate PDX models in the SRG rat system?

Based on current research methodologies, comprehensive molecular characterization of PDX models in the SRG rat should include:

• Histopathological analysis with H&E staining to assess tumor morphology, necrosis, and stromal interactions

• Immunohistochemistry for key markers such as Ki67 (proliferation)

• FACS analysis to confirm absence of immune cells (using markers such as PE mouse anti-rat IgM, APC Mouse anti-rat CD45R, PE Mouse Anti-Rat CD8a, APC Mouse Anti-Rat CD4, and APC Mouse Anti-Rat CD161a)

• Single-cell spatial imaging to evaluate gene expression patterns

• Comparison of multiple passages (P1, P2, P3) to the original patient sample to confirm model stability

These multi-modal approaches help ensure that PDX models maintain high concordance with original patient samples across passages and accurately recapitulate human disease.

What are the optimal antibody characterization strategies when working with SRG rat models?

When characterizing antibodies for use with SRG rat models, researchers should employ multiple validation strategies following the "five pillars" approach:

For SRG-specific studies, genetic strategies are particularly valuable as they can confirm antibody specificity against the engineered knockout background of the model .

How should researchers design experiment protocols to accurately compare drug efficacy in SRG rat PDX models versus traditional mouse models?

To ensure scientifically valid comparisons between SRG rat and mouse PDX models for drug efficacy studies, protocols should include:

• Matched tumor fragment sizes and implantation techniques for both models

• Randomization of animals into treatment groups once tumors reach a standardized size (typically 100-200 mm³)

• Consistent drug dosing regimens adjusted for body weight differences

• Parallel sampling timepoints for both models (blood, tissue, etc.)

• Statistical power calculations accounting for the reduced animal numbers needed with SRG rats

• Collection of multiple endpoints from each animal in the SRG rat cohort (efficacy, pharmacokinetics, clinical pathology, toxicity, systemic exposure, and biomarker data)

This approach maximizes the information obtained while potentially reducing the total number of animals required, which aligns with 3R principles.

What considerations should be made when designing an experiment to study the bystander effect of antibody-drug conjugates in SRG rat PDX models?

When investigating bystander effects of antibody-drug conjugates (ADCs) such as those observed with SGN-35 (anti-CD30 ADC) in SRG rat PDX models, researchers should consider:

• Creating mixed tumor cell populations with target-positive and target-negative cells (e.g., CD30+ and CD30- cells) at defined ratios

• Employing fluorescent labeling or other markers to distinguish between cell populations

• Measuring dose-dependent cytotoxicity across the mixed population

• Analyzing drug release kinetics within tumor tissue (using techniques like radiometric and LC/MS-based assays)

• Assessing intracellular drug concentrations and retention times in both target-positive and target-negative cells

• Determining the membrane permeability characteristics of the released payload (like MMAE, which has demonstrated 15-20 hour retention half-life in target cells)

This experimental design helps quantify the extent to which released drug from target-positive cells affects neighboring target-negative cells, a key mechanism for many ADCs.

How should researchers design longitudinal studies to evaluate metastasis patterns in SRG rat PDX models?

For longitudinal metastasis studies in SRG rat PDX models, researchers should implement:

• Non-invasive imaging protocols (MRI, PET-CT, or bioluminescence imaging) to track primary tumor growth and potential metastatic sites

• Sequential blood sampling to identify circulating tumor cells or cell-free DNA

• Stratified endpoint analysis with animals euthanized at different timepoints to characterize the progression of metastasis

• Comprehensive tissue collection protocol covering common metastatic sites beyond primary tumor location

• Molecular characterization comparing primary tumor and metastatic lesions to assess clonal evolution

• Integration of these data with patient clinical outcomes when applicable

The SRG rat model is particularly advantageous for such studies because it allows for repeated blood sampling and can support larger tumors before requiring euthanasia, enabling more extensive metastatic progression than mouse models .

How should researchers account for species-specific differences when interpreting gene expression data from PDX models grown in SRG rats?

When analyzing gene expression data from PDX models in SRG rats, researchers should:

• Implement bioinformatic pipelines that can distinguish between human (tumor) and rat (host) transcripts

• Normalize data accounting for the different proportions of human vs. rat cells in different PDX samples

• Apply statistical adjustments for the increased variability in stromal content between SRG rat PDXs

• Compare expression patterns of key genes like TCIM and CXCL2 that show differential regulation in rat vs. mouse hosts

• Validate findings through orthogonal methods such as immunohistochemistry or in situ hybridization to confirm cellular source of signals

Analysis should recognize that the SRG rat may influence human gene expression in the transplanted tumor, potentially allowing expression patterns more closely resembling the original patient tumor due to more favorable microenvironmental interactions .

What statistical approaches are recommended for analyzing differential drug responses between SRG rat and NSG mouse PDX models?

For robust statistical analysis of differential drug responses between host species, researchers should employ:

• Power analysis that accounts for the typically reduced variance in SRG rat models

• Mixed-effects models that incorporate both fixed effects (drug, dose, host species) and random effects (individual PDX line, passage number)

• Survival analysis methods (Kaplan-Meier estimates, Cox proportional hazards models) for time-to-endpoint comparisons

• Multivariate approaches that can correlate drug response with molecular characteristics of the PDX

• Cross-validation techniques to ensure findings are generalizable across PDX models

When possible, use matched PDX models derived from the same patient sample grown in both host species to control for tumor heterogeneity, and consider implementing Bayesian approaches that can incorporate prior knowledge about drug mechanisms and expected efficacy profiles.